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Expression Analysis of the Imprinted Gene Transketolase-like 1 in Mouse and Human

Amy Frances Friss
University of Connecticut

Abstract
Genomic imprinting is an epigenetic phenomenon resulting in differential gene
expression based on parental origin. Recently, transketolase-like 1 (TKTL1) has been
identified as an X-linked imprinted gene. TKTL1 functions in the nonoxidative branch of
the pentose phosphate pathway (PPP), which maintains glutathione in a reduced state
through the generation of NADPH. Previous studies on transaldolase, the other critical
enzyme in the nonoxidative branch of the PPP, suggest that TKTL1 may affect the cell’s
ability to reduce glutathione. This study provides evidence that TKTL1 overexpression
inhibits glutathione reduction. Intriguingly, aberrant glutathione levels are associated
with autism. Additionally, studies involving Turner syndrome females found that
differences in social behavior could distinguish females expressing the maternal X
chromosome from those expressing the paternal X chromosome. This led researchers to
hypothesize the influence of an X-linked imprinted gene in autism. Accordingly, this
study compared TKTL1 expression levels in autistic patients versus their unaffected
siblings. The results suggest that further studies are required.
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Chapter 1: Background Information

1.1 Epigenetics and Imprinting
Genomic imprinting is an epigenetic phenomenon resulting in parent-of-origin
gene expression. Epigenetic mechanisms mediate genomic imprinting, leaving the DNA
sequence unchanged. These mechanisms primarily include DNA methylation patterns
and histone modifications. The epigenetic marking of an imprinted gene’s alleles
designate their parental origin, allowing for appropriate expression patterns in the soma1.
Differential DNA methylation is the hallmark of imprinted genes. A differentially
methylated region (DMR) is only methylated on one parental allele, typically on the
cytosine of CpG dinucleotides2. Often, DMRs constitute imprinting control regions
(ICRs)2. The imprint is established in the germline and is maintained throughout genomewide demethylation during preimplantation development1. Deletion of an imprinted
gene’s ICR can result in loss of imprinted gene expression or reversion to biallelic
expression1.
DNA methylation is regulated by DNA methyltransferases (DNMTs), which are
classified as de novo methyltransferase or maintenance methyltransferase. DNMT3A and
DNMT3B are the de novo methyltransferases, assisted by the DNMT3L protein. Though
it is homologous to DNMT3A and DNMT3B, DNMT3L has no catalytic activity3 but is
still a regulator of imprint establishment4. Research demonstrated DNMT3L association
with DNMT3A only in species in which imprinting occurs, suggesting that DNMT3L
acquisition may have been related to the evolution of imprinting.5 Together, DNMT3A
and DNMT3L are responsible for de novo methylation of most ICRs. Hemimethylated
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DNA is methylated by DNMT1, the enzyme necessary for maintaining DNA methylation
at imprinted loci and across the genome.
Histones exhibit post-translational modifications including methylation and
acetylation. Methylation of specific amino acid residues occurs via histone
methyltransferase. Actively transcribing regions are typically methylated on arginine
residues whereas methylation of lysine (K) residues is typically associated with
repression, except for H3K4 trimethylation6 and H4K20 monomethylation7 which result
in active transcription. Histones are acetylated or deacetylated using histone
acetyltransferase (HAT) or histone deacetylase (HDAC), respectively. Upon acetylation,
chromatin is transformed into a more relaxed structure that is associated with more
actively transcribing DNA. The acetyl group carries a negative charge that interacts with
the positively charged histones to create a neutral environment. A neutral environment
decreases the histones’ interaction with the negatively charged DNA, providing greater
accessibility for transcription factors.
Chromatin packages DNA into a structure that fits into the cell and is strong for
support during mitosis and meiosis. Chromatin is composed of histone octamers, dimers
of subunits H2A, H2B, H3 and H4, wrapped in DNA, forming a nucleosome8. The
different states of chromatin control gene expression and DNA replication:
heterochromatin is associated with non-transcribing regions; euchromatin with actively
transcribing regions.
Imprinted genes are generally found in 1Mb clusters controlled by one ICR1.
Clusters are typically regulated in one of two ways, including use of an insulator to
control access to the shared regulatory elements of the cluster and silencing of the cluster
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by noncoding RNA (ncRNA)1. The H19/Igf2 locus is controlled by the insulator
mechanism, while ncRNA regulates the Igf2r cluster in mouse9.
H19 is a paternally imprinted (maternally expressed) gene on mouse chromosome
7, coding for a 2.2Kb non-coding RNA10. Insulin-like growth factor 2 (Igf2) is a
maternally imprinted (paternally expressed)11,12 gene influencing fetal growth and is
found within the same cluster as H19. Both genes share an enhancer13 and are controlled
by the same ICR14,15. On the maternal allele the ICR binds CTCF, a protein that mediates
insulator activity at the β-globin locus16. CTCF binding blocks interaction of Igf2 with the
enhancers, while H19 retains access and proceeds with transcription17. The ICR is
methylated on the paternal allele, blocking CTCF binding and preventing H19 from
interacting with the enhancers while Igf2 maintains interaction9 (Figure 1.1).

Figure 1.1 Imprinted H19/Igf2 cluster. Figure adapted from Bartolomei et al1.

More commonly, ncRNAs appear to regulate imprinting in clusters18, as in the
insulin-like growth factor 2 receptor (Igf2r) cluster on mouse chromosome 17A19 (Figure
1.2).The Igf2r cluster consists of maternally expressed genes Igf2r, solute carrier 22a2
and 22a3 (Slc22a22 and Slc22a3, respectively), paternally expressed antisense Igf2r
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RNA (Airn) and a few non-imprinted genes. Airn is a 108 kb ncRNA that is arranged in
an antisense orientation to Igf2r, with its promoter located in the cluster’s ICR1. On the
maternal chromosome the ICR is hypermethylated, preventing Airn transcription but
allowing transcription of Igf2r, Slc22a22 and Slc22a3. On the paternal copy, the ICR is
unmethylated; however the Igf2r promoter is methylated after transcription initiation of
the imprinted gene. Igf2r promoter methylation leads to transcription of Airn while the
other 3 imprinted genes in the cluster are not transcribed. While it is known that Airn
expression leads to gene silencing, the mechanism remains to be determined1.

Figure 1.2 Imprinted Igf2r cluster. Figure adapted from Bartolomei et al1.

1.2 X-Linked Imprinting
While most imprinted genes are found on autosomes, a subset has been identified
on the X chromosome20. Most X-linked genes, imprinted and non-imprinted, are subject
to X chromosome inactivation in female mammals; one X chromosome in each cell is
randomly inactivated as a form of dosage compensation to equate for the single
(maternal) X chromosome in male cells. A counting mechanism ensures that each cell
maintains only one active X chromosome per diploid cell21. The inactive X chromosome
is a Barr body and is visualized in somatic cells as compact chromatin.
4

X chromosome inactivation is mediated by the X chromosome inactivation center
(XIC) which contains several elements that may play a role in inactivation. One such
element is the X-chromosome-controlling element (XCE)22. The X chromosome carrying
the stronger XCE is more likely to remain active, leading to unequal X inactivation.
Other elements include the genes XIST (X (inactive)-specific transcript)23 and TSIX (X
(inactive)-specific transcript, antisense)24. XIST encodes a 17 Kb noncoding RNA
molecule that accumulates along the X chromosome containing the active XIST gene,
resulting in inactivation of most genes on that chromosome with few exceptions. TSIX,
also a noncoding transcript, is synthesized on the strand antisense to XIST and at the onset
of X-inactivation extends along the entire XIST gene of the X chromosome destined to
remain active. While it is known that TSIX regulates XIST expression in cis, the
mechanism by which this occurs is undetermined.
X chromosome inactivation complicates X-linked imprinting by influencing the
expression level of X-linked imprinted genes in females. For example, a paternally
imprinted gene will be expressed in approximately half of a female’s cells. The other half
of cells with an inactive maternal X chromosome will have low, if any, expression of the
paternally imprinted gene. In comparison, males will express this paternally imprinted
gene from their single (maternal) X chromosome in every cell. Consequently, males will
exhibit higher expression of this gene than females. The expression difference may
contribute to sex-specific differences seen between males and females.
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1.3 Search for X-Linked Imprinted Genes
A search for X-linked imprinted genes was performed using a mouse model for
Turner syndrome (39,Xm and 39,Xp)25. The search led to the gene X-linked lymphocyte
regulated (Xlr), of which fifteen paralogs have been identified. Of these fifteen, three
have been identified as imprinted genes: Xlr3b, Xlr4b and Xlr4c are repressed on the
paternal X chromosome25. The Xlr3 and Xlr4 gene clusters are in a region of high
homology that is highly conserved between mouse and human. In humans, this region is
located near the end of Xq28, however no human homologs of any Xlr gene have been
identified. In addition, the function of Xlr proteins remains unclear.
Following identification of the imprinted mouse Xlr genes, Dr. Addie May
Nesbitt expanded the search for X-linked imprinted genes. Because imprinted genes are
typically found in clusters, her search included four genes in a region 1 Mb downstream
of the Xlr locus and one gene 2Mb upstream: Filamin alpha or Actin binding protein
280/Abp280 (Flna), B cell receptor associated protein 31 (Bcap31), Inhibitor of kappa B
kinase gamma (Ikbkg), Transketolase-like 1 (Tktl1) and Cd99 antigen-like 2 or Xap89
(Cd99l2). All but one gene displayed biallelic expression in E9.5 embryo, E9.5 placenta
and E14.5 liver. The exception was Tktl1 in liver, where there was a statistically
significant difference between the different genotypes. 39,Xm Tktl1 expression was about
14-fold higher than 39,Xp, while 40,XX expression was in between 39,Xm and 39,Xp
with the expression level closer to 39,Xp. Since X-linked imprinted genes have been
implicated in neurocognitive disorders, a variety of brain subregions were assayed as well
and analysis found increased Tktl1 expression in brain subregions of 39,Xm.
Subsequently, Tktl1 became the focus of X-linked imprinting studies.
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Upon confirmation of Tktl1 imprinting in mice, the search for a human ortholog
began. Human brain subregions from a 19 week 40,XX female indicate tissue specific
imprinting of TKTL1. The hypothalamus, midbrain, frontal cortex and thalamus all
displayed higher TKTL1 expression from one X chromosome while the temporal cortex
did not show an imprint. Assays using human lymphoblastoid cells from Turner
syndrome individuals demonstrated higher TKTL1 expression from the maternal X
chromosome. Taken together, these results indicate that Tktl1/TKTL1 is paternally
imprinted in both mouse and human.
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CHAPTER 2: TKTL1 Overexpression Studies

2.1 Background Information
Pentose Phosphate Pathway
Glucose metabolism in the cell occurs via two main biochemical pathways: the
Embden-Meyerhof pathway and the pentose phosphate pathway (PPP). The EmbdenMeyerhof pathway degrades glucose to provide lactic acid and ATP in anaerobic
conditions. The PPP exists in the cytoplasm of the cell (Figure 2.1), producing the
reducing equivalent NADPH (reduced nicotinamide adenine dinucleotide phosphate) and
ribose for ribose nucleic acid. The PPP consists of two branches: the oxidative branch
and the nonoxidative branch. The oxidative branch of the PPP is unidirectional, whereas
the nonoxidative branch is fully reversible. NADPH is produced in the oxidative branch
via the enzymes glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate
dehydrogenase (6PGD). In the nonoxidative branch, the forward reactions produce
glyceraldehyde-3-phosphate and fructose-6-phosphate while the reverse reactions
produce ribose-5-phosphate.
Transaldolase (TAL) and Transketolase (TK) comprise the enzymes of the PPP’s
nonoxidative branch. TAL catalyzes two reactions: glyceraldehydes-3-phosphate to
fructose-6-phosphate; sedoheptulose-7-phosphate to erythrose-4-phosphate. TK catalyzes
the following: xylulose-5-phosphate and ribose-5-phosphate to sedoheptulose-7phosphate or glyceraldehydes-3-phosphate; xylulose-5-phosphate and erythrose-4phosphate to glyceraldehydes-3-phosphate or fructose-6-phosphate. Conflicting results
have been obtained as to which is the rate-limiting enzyme of this branch26,27,28,29.
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Figure 2.1 The pentose phosphate pathway of glucose metabolism. The oxidative branch
begins at glucose-6-phosphate and produces ribulose-5-phosphate, which leads into the
nonoxidative branch.

9

TK transfers a two carbon unit (1,2-dihydroxyethyl) in a two-substrate reversible
reaction from ketose phosphates to aldose phosphates. TK is a thiamine-dependent
transferase and therefore requires thiamine diphosphate, along with Ca2+, as
cofactors30,26. The forward reactions catalyzed by TK produce glyceraldehyde-3phosphate and fructose-6-phosphate which are utilized by glycolytic pathways or
converted into glucose-6-phosphate and reintroduced into the PPP. In the reverse
reaction, TK produces ribose-5-phosphate which is necessary for nucleic acid synthesis.
TK has been implicated in neurodegenerative diseases, diabetes and cancer31.
Thiamine deficiency in humans leads to the neuropsychiatric disorder Wernicke’s
encephalopathy (WE), which is encountered in chronic alcoholics and patients with
impaired nutrition associated with gastrointestinal disease or AIDS32. In Alzheimer’s
disease, varied TK proteins with different isoelectric points have been detected. Altered
TK activity is not implicated in other neurological diseases, making this characteristic for
Alzheimer’s disease and a potential biomarker33. Diabetes patients have high blood
glucose levels resulting in nonenzymatic glycation which causes vascular complications,
neuropathy and retinopathy by producing advanced glycation end products34. Treatment
with vitamin B1 (thiamine derivative benfotiamine) supplements activates TK, blocking
three major pathways of hyperglycemic damage35. In cancer, some cells produce more
than 85% of ribose for nucleic acid synthesis directly or indirectly from the nonoxidative
branch of the PPP due to increased enzymatic activity36. Specifically, transketolase-like 1
upregulation occurs in cancer cells37, providing a novel target for cancer patient nutrition
and treatment.
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Transketolase-like 1
One transketolase gene, transketolase (TK), and two transketolase-like genes,
transketolase-like 1 (TKTL1) and transketolase-like 2 (TKTL2), have been identified.
TKTL1, initially described by Coy et al. in 1996 as a transketolase-related gene, contains
a stop codon in a putative exon which causes deletion of that exon. The deletion mutates
one of the two thiamine binding sites in the gene. Because of the pseudoexon it was
thought that TKTL1 was a pseudogene, however Coy et al. later demonstrated
transketolase activity31. TKTL1 encodes a tissue-specific spliced exon, causing formation
of TKTL1 transcripts which produce full length and smaller proteins and encode tissuespecific protein isoforms. While TKTL1 acts as a transketolase, it also has altered
enzymatic activity. Coy et al. found that TKTL1 has broader substrate utilization than
TK, as well as an enhanced one-substrate reaction31.
TKTL1 is the sole transketolase upregulated in tumor cells, potentially due to its
location; Xq28 is one of a few regions activated in malignancies and during the cell
cycle39,40. Cancer cells naturally overexpressing TKTL1 have an increased amount of
reduced glutathione (GSH) and NADPH compared to similar cells in which TKTL1 has
been silenced with siRNA41. In cancer cells, upregulation of TKTL1 is thought to increase
flow through the oxidative branch of the PPP, leading to increased NADPH production
and subsequently increased GSH production. The GSH increase would neutralize free
radicals, characteristic of cancer cells, allowing the cancer cell to combat oxidative stress.
Silencing TKTL1, however, causes the cancer cell to succumb to oxidative stress and
apoptose.
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2.2 Overexpression Studies
Functional analysis of TKTL1 overexpression remains to be performed.
Specifically, the effect of TKTL1 overexpression on oxidative stress has not been studied.
The effect of TAL overexpression, however, has been analyzed.
TAL overexpression in Jurkat human T cells leads to decreased enzymatic
activities of G6PD and 6PGD and decreased NADPH and GSH levels42. Based on these
results and others, Banki et al. proposed that TAL plays a critical role in regulating the
balance between the oxidative and nonoxidative branches of the PPP42. I hypothesized
that similar results would be obtained upon overexpression of TKTL1, coding for the
other critical enzyme of the nonoxidative branch of the PPP.
I aimed to determine the effect of TKTL1 overexpression on oxidative stress.
Overall, I hypothesized that TKTL1 overexpression would lead to increased cellular
oxidative stress as measured by the effect of TKTL1 overexpression on GSH levels.
NADPH and G6pdx expression levels were also analyzed in effort to determine TKTL1’s
effect on the PPP. An immortalized mouse hippocampal cell line (HT-22, gift from the
laboratory of Dr. Walikonis) was used for transfection. The HT-22 cell line is a
glutamate-sensitive subclone from an HT-4 cell line. HT-4 cells were derived from
mouse neuronal tissue immortalized with a temperature-sensitive SV40 T-antigen that
adopted properties of differentiated neuronal cells at the nonpermissive temperature.
TKTL1 was overexpressed by transfecting HT-22 cells with the human TKTL1 gene,
allowing visualization of the resulting protein by Western blot analysis separately from
the mouse protein based on antibody specificity and thus demonstrating TKTL1
overexpression.
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Construct Formation
pCAGGS (gift from the laboratory of Dr. LoTurco), a 4801bp plasmid with a
constitutive chicken β-actin promoter allowing for constant expression, was used for
transfection (Supplemental Figure 1). The human TKTL1 sequence was inserted into the
vector by restriction enzyme digestion and ligation (Protocol 1) and selected for in
Escherichia coli by the ampicillin resistance cassette on pCAGGS.

Transfection
TKTL1 was overexpressed in HT-22 cells by transfection using Lipofectamine™
LTX (Protocol 2). A GFP-pCAGGS construct (gift from the laboratory of Dr. Walikonis)
was co-transfected with the hTktl1-pCAGGS construct in order to visualize transfection
efficiency. Green fluorescent protein (GFP) was produced in the cells by the GFPpCAGGS construct, presumably representing the transfection efficiency of hTktl1pCAGGS as well. The images in Table 2.1, captured by an inverted microscope, illustrate
the GFP expression and the confluency of HT-22 cells on the day they were harvested.
There appears to be high transfection efficiency.
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Trial
1

Control
NA

Sample
NA

NA

NA

2

3
4A

4B

5A

14

5B

6A
6B

NA
NA

NA
NA

7A

7B

7C

15

8A

8B

8C

8D

16

9A

9B

NA

NA

9C

9D

Table 2.1 The first column contains the transfection trial designation. The second column
contains images of HT-22 cells transfected with GFP-pCAGGS and pCAGGS (control).
In the third column are images of HT-22 cells transfected with GFP-pCAGGS and
hTktl1-pCAGGS (sample). Each box contains images of transfected HT-22 cells without
visualizing the fluorescence on top and images showing the GFP expression on bottom,
thereby indicating the expression of control or hTktl1-pCAGGS. “NA” means that
images were not available for the indicated trials.
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Western Blot Analysis
After the transfected HT-22 cells were harvested a Western blot was performed to
confirm the absence and presence of human TKTL1 in control and sample cells,
respectively (Protocol 3). Goat anti-human TKTL1 bound to TKTL1 in hTktl1-pCAGGS
transfected cells, but not in control cells, confirming expression of human TKTL1 only in
hTktl1-pCAGGS transfected cells (Table 2.2). Therefore, overexpression of TKTL1 is
indicated in cell samples and not controls.

Trial

Western Blot Image
Control
Sample

1

2

NA
Control

Sample

3

Control

Sample

4A

Control

Sample

4B

18

Control

Sample

5A

Control

Sample

5B

Control

Sample

6A

Control

Sample

6B

Control A

Sample A

Control B

Sample B Control C Sample C

7

Control A*

Sample A

Control B

Sample B

8

*Sample A spilled over into the well for Control A upon loading the gel.
This control/sample pair was excluded from use in future assays.
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Control C

Sample C

Control D Sample D

8

Control A

Sample A

Control B

Sample B

9

Control C

Sample C

Control D

Sample D

9

Table 2.2 Detection of the human TKTL1 protein by Western blot in HT-22 cell lines
after transfection with GFP-pCAGGS and control (pCAGGS) or hTktl1-pCAGGS
(sample). The primary antibody was specific to human TKTL1 and the protein band size
is 65kDa. Primary and secondary antibodies bound only to the sample transfected with
hTktl1-pCAGGS. A negative control with secondary antibody only was performed with
all controls and samples and resulted in a lack of protein bands (data not shown),
demonstrating primary antibody specificity.

TKTL1 Expression Analysis
Primers were designed that captured both the mouse and human TKTL1 gene
sequence (Supplemental Table 1), made possible by the high sequence homology shared
by mouse and human TKTL1. Real-time RT-PCR was performed using the designed
primers and RNA from control and hTktl1-pCAGGS transfected HT-22 cells (Protocols 4
and 5). The results demonstrate that TKTL1 gene expression is millions of times greater
in hTktl1-pCAGGS transfected cells versus control cells (Figure 2.2); however there is
no relation to the amount of TKTL1 protein in the cell samples. Since Western blot
20

analysis revealed human TKTL1 protein in only the hTktl1-pCAGGS transfected cells, it
is reasonable to assume that total TKTL1 protein content is greater in the sample cells
than the control cells. Therefore, TKTL1 is overexpressed in hTktl1-pCAGGS transfected
cells compared to control cells.

TKTL1 Expression
Relative Expression Ratio

4.50E+06

3.71E+06

4.00E+06
3.50E+06
3.00E+06
2.50E+06
2.00E+06
1.50E+06
1.00E+06
5.00E+05

1.40E+00

0.00E+00
Control

Sample

Figure 2.2 Real-time RT-PCR of TKTL1 in control and hTktl1-pCAGGS transfected HT22 cells. TKTL1 transcription level increased by approximately 3 million fold in the
hTktl1-pCAGGS transfected cells. The translation level of the gene is not reflected. Error
bars indicate a 95% confidence interval.

Glutathione Assay
The Glutathione Assay kit from Cayman Chemical was used to determine the
amounts of reduced and oxidized glutathione (GSH and GSSG, respectively) in control
and hTktl1-pCAGGS transfected cells (Protocol 6). The kit relies on a colorimetric
reaction where GSH reacts with 5,5’-dithio-bis-2-(nitrobenzoic acid) (DTNB) to produce
5-thio-2-nitrobenzoic acid (TNB), which has a yellow color. GSHTNB is concomitantly
21

produced and reduced by glutathione reductase to recycle the GSH and produce more
TNB. The rate of TNB production is directly proportional to the GSHTNB to GSH
reaction, which is directly proportional to the concentration of total glutathione. The
absorbance of the yellow TNB at 405nm provides an estimation of total glutathione in a
sample. In order to determine GSH amount alone, GSSG can be measured and subtracted
from the total glutathione. Measurement of GSSG is performed similarly to total
glutathione measurement, but with the addition of 2-vinylpyridine to the sample to
derivatize glutathione. GSH and GSSG concentrations were calculated using the end
point analysis method. Statistical methods were also used to analyze the data.

Glutathione Assay Results
Nine different HT-22 cell lines were assayed for GSH and GSSG, four of which
resulted in negative amounts of GSSG in control and/or hTktl1-pCAGGS transfected
cells. In other words, the absorbance values were less than the 0mM GSSG standard
absorbance potentially due to negligible amounts of GSSG, insufficient cell
concentration, or interference as suggested through communications with Cayman
Chemical technical support. The cell samples were concentrated as much as possible and
in some cases resulted in positive amounts of GSSG, while others remained negative.
Figure 2.3 displays the GSH/GSSG redox ratio for the five trials that resulted in
positive concentrations. The ratio for trials 3, 6 and 8 decreased upon overexpression of
TKTL1, while Trials 7 and 9 showed no difference. The GSH/GSSG ratios and standard
deviations can be found in the supplemental information (Table 2).
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GSH / GSSG
12

GSH / GSSG (µM)

10
8
6

Control

4

Sample

2
0
Trial 3

Trial 6

Trial 7

Trial 8

Trial 9

Figure 2.3 GSH/GSSG in control and hTktl1-pCAGGS transfected HT-22 cells. These
were the trials that resulted in positive concentration values. TKTL1 overexpression
resulted in decreased GSH/GSSG ratios or no difference. Error bars indicate a 95%
confidence interval.

The raw absorbance values obtained for all nine glutathione assays were also
analyzed. Initially, the proportion of GSH in each cell sample was calculated (Table 2.3
and Figure 2.4) using the formula ( (GSH – GSSG) / GSH). Since GSH in the assay
represents total glutathione, the absorbance value for oxidized glutathione was subtracted
from the GSH value to give the value for reduced GSH.
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GSH / Total Glutathione
Trial #
1
2
3
4
5
6
7
8
9

Control
0.21173
0.71477
0.57010
0.75465
0.78521
0.47580
0.11657
0.60528
0.38604

Sample
0.15589
0.59042
0.43391
0.74759
0.71819
0.11955
0.12729
0.55941
0.40499

Table 2.3 Proportion of GSH in control and hTktl1-pCAGGS transfected cells.

GSH / Total GSH
0.9
0.8

GSH / Total GSH

0.7
0.6
0.5
0.4

Control

0.3

Sample

0.2
0.1
0.0
1

2

3

4

5

6

7

8

9

Trial Number

Figure 2.4 Proportion of GSH in control and hTktl1-pCAGGS transfected cells for all
nine trials. Five trials resulted in a decreased proportion upon TKTL1 overexpression,
four trials displayed no change. Error bars indicate a 95% confidence interval.
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A boxplot was then constructed to visualize the data (Figure 2.5). The boxplot
illustrates that the proportion of GSH in HT-22 cells decreased upon TKTL1
overexpression. The decrease is statistically significant (P = 0.029) as determined by a
one-tailed T-test.

Figure 2.5 Boxplot of the proportion of GSH in control and hTktl1-pCAGGS transfected
HT-22 cells using raw absorbance values (P= 0.029).
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Glutathione Assay Analysis
Taken together, the analysis of the concentrations of GSH and GSSG in control
and hTktl1-pCAGGS transfected cells and the analysis of the proportion of GSH in the
cells based on raw absorbance values indicate that TKTL1 overexpression decreases the
amount of GSH in the cell. Presumably, the cell would not be able to readily reduce free
radicals, causing a state of oxidative stress. Based on the PPP, TKTL1 indirectly affects
glutathione through influencing NADPH production. I hypothesized that NADPH will
also be decreased, providing a mechanism which hinders GSH production.

NADPH Experiments
The NADP+/NADPH Assay kit from BioAssay was used to determine the ratio of
NADPH/NADP+ in the control and hTktl1-pCAGGS transfected cells (Protocol 7). The
kit has a procedure to extract NADP+ and NADPH from the cells using provided buffers.
NADP+ and NADPH are then measured by a colorimetric reaction where formed
NADPH reduces a formazan (MTT) reagent, which produces a color that is measured at
565nm. This color is proportionate to the NADP+/NADPH concentration in the sample.

NADPH Assay Results
Five different HT-22 cell lines were assayed for NADP+ and NADPH. Of the
five, three displayed a decrease in the NADPH/NADP+ ratio upon TKTL1
overexpression, one increased and one resulted in no change (Figure 2.6). The NADPH
and NADP+ concentrations and their ratio can be found in Supplemental Table 3.
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Figure 2.6 NADPH/NADP+ ratio for trials 1 through 5. TKTL1 overexpression resulted
in decrease, increase, or no change. Error bars indicate a 95% confidence interval.

NADPH Assay Analysis
Further analysis of NADPH/NADP+ is needed in order to provide a conclusive
statement about the effect of TKTL1 overexpression on the NADPH/NADP+ ratio. The
results suggest that there is an effect on the NADPH/NADP+ ratio since the ratio
decreased in three out of five trials when TKTL1 was overexpressed. Since GSH was
demonstrated to decrease, it was expected that NADPH would provide the same result.
The hypothesized mechanism was that a decrease in NADPH would lead to a decrease in
GSH, since NADPH reduces GSSG.
A decrease in the NADPH/NADP+ ratio would indicate that overexpression of
TKTL1 decreases the amount of NADPH produced by the cell. Since increase, decrease
and no change were all seen, it is possible that NADPH from other sources in the cell is
skewing the result. A different assay may be needed to determine the effect of TKTL1
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overexpression on NADPH/NADP+, if any. Based on the Banki et al. paper, it is expected
that NADPH will be affected.

G6pdx Expression
Real-time RT-PCR was performed to analyze G6pdx expression in control and
hTktl1-pCAGGS transfected cells (Protocol 5). Analysis demonstrated a significant
decrease of G6pdx when TKTL1 was overexpressed (Figure 2.7).

Relative Expression Ratio

G6pdx Expression
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0

1.7043

1.0426

Control

Sample

Figure 2.7 Real-time RT-PCR of G6pdx, coding for G6PD in mouse, in control and
hTktl1-pCAGGS transfected HT-22 cells. G6pdx levels significantly decreased upon
TKTL1 overexpression (P = 0.000135). Error bars indicate a 95% confidence interval.

G6pdx Expression Analysis
A decrease in G6pdx may lead to a decrease in NADPH production since G6pdx
catalyzes the production of NADPH. Furthermore, less NADPH would be available in the
cell to reduce GSSG to GSH, causing a decrease in GSH in the cell and leading to
oxidative stress.
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Discussion
G6pdx expression decreased due to overexpression of TKTL1. It was thought that
this decrease would reduce the amount of NADPH produced in the cell. While the results
point toward this effect, no conclusion can be made about the actual effect, if any, on
NADPH. Assuming there were less NADPH available, the ability of the cell to reduce
glutathione would be inhibited. The results demonstrate that the amount of GSH in the
cell decreased in response to TKTL1 overexpression. Based on this result, I determine
that the cell is in a state of oxidative stress due to overexpression of TKTL1. To confirm
this, direct analysis of reactive oxygen species (ROS) levels would be necessary.
Increased ROS levels are expected based upon the results of this study and would support
the conclusion of oxidative stress. The increase in ROS levels would also increase the
cell’s sensitivity to apoptosis, which is measurable as well. This was the result upon TAL
overexpression42 and I hypothesize the same effect for TKTL1 overexpression. Therefore,
future analysis may conclude that TKTL1 levels in the cell play a role in programmed cell
death.
ROS, including superoxide, hydroxyl, hydrogen peroxide, singlet oxygen and
nitric oxide, cause cellular damage and maintain importance in autism43. Increased ROS
levels have been found in patients with autism, as well as in other neuropsychiatric
conditions44. Impairment in the cell’s antioxidant defense system may contribute to this
increase. Patients with autism have a decreased amount of reduced GSH compared to
unaffected individuals45 which decreases the cell’s capacity to reduce ROS and leads to
oxidative stress. It is unclear, however, if oxidative stress contributes to the pathogenesis
of autism, or if it is a secondary manifestation of the disorder45.
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Chapter 3: Human Lymphoblast Autism Studies

3.1 Background Information
Autism
Autism is a neurodevelopmental syndrome with genetic and nongenetic causes,
characterized by a variety of phenotypes. According to the Diagnostic and Statistical
Manual of Mental Disorders: DSM-IV-TR there are three criteria for diagnosing autism:
impairment in 1) social interaction and 2) communication and 3) restricted patterns of
behavior, interests and activities. If a patient has severe impairment in several criteria but
not all, the DSM-IV-TR identifies the disorder as pervasive developmental disorder, or
autism spectrum disorder (ASD) including autistic disorder, Rett’s Disorder, childhood
disintegrative disorder, Asperger’s disorder, and pervasive developmental disorder not
otherwise specified.
Nongenetic factors, such as oxidative stress, contribute to the pathogenesis of
autism and several other neuropsychiatric disorders due to the brain’s vulnerability to
oxidative stress46. Research shows lowered levels of the antioxidant enzymes glutathione
peroxidase and superoxide dismutase in autistic individuals, denoting impaired
antioxidant defense mechanisms47. Additionally, patients with autism displayed reduced
levels of total glutathione and a lowered GSH/GSSG redox ratio48. Supplementation with
methyl B12 improved blood glutathione levels and the GSH/GSSG redox ratio in 30% of
test subjects, indicating methyl B12 as a potential beneficial autism treatment49. Genetic
and environmental effects may increase vulnerability to oxidative stress in autism.
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Inconsistent linkage and association results50, as well as low sibling recurrence
compared to single-gene diseases51, support the genetic complexity of autism. Multiple
genetic loci on several chromosomes have been linked to autism or ASD52. While some
genes are directly linked to autism, others are thought to contribute indirectly by
increasing an individual’s susceptibility to the disorder. The complex inheritance patterns
formed by the combination of multiple genes that interact with each other and the
environment remain unknown. Recently, de novo copy number variation mutations have
been associated with a subset of ASD cases, typically of individuals with older fathers,
leading researchers toward a new mode of inheritance53. One example is the
chromosomal region 15q11-q1354. This region is an original region associated with
autism and is also imprinted in Angelman and Prader-Willi syndromes (AS and PWS,
respectively)55. An imprint mutation causes either AS or PWS depending on parental
mode of inheritance.
Several disorders are consistently associated with ASD, such as fragile X,
Angelman and Prader-Willi syndromes, among others, however these cases account for
only a small percentage of ASD diagnoses. Notably, all ASD-related syndromes are
limited to the brain56.
Genome-wide association studies (GWAS) are becoming increasingly important
in the study of autism. GWAS have demonstrated that not only is rare variation important
in autism, but common variation is as well. GWAS have identified regions and single
nucleotide polymorphisms linked or associated with autism. The chromosomal region
15p14.1 is an example of a common variation region57. Two genes previously connected
to ASD, RyR2 and UPP2, were also identified by GWAS as autism-associated genes58.
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Autism is diagnosed four times as often in males as in females indicating
involvement of an X-linked imprinted gene in autism59. Turner syndrome studies by
Skuse et al. point toward an X-linked gene that is paternally expressed60.

Turner Syndrome and Skuse Hypothesis
Turner syndrome is characterized by complete or partial absence of one X
chromosome in some or all of a female’s cell lines due to failed sex chromosome
segregation. Turner individuals tend to have clinical problems, such as cardiovascular
and kidney problems, and exhibit social behavior problems; however their intelligence is
typically normal. Skuse et al. found that differences in social behavior could distinguish
45,Xp females from 45,Xm females60. The study showed that 46,XX and 45,Xp females
had superior social cognitive skills than 46,XmY males and 45,Xm females indicating that
a gene expressed only from the paternal X chromosome is involved in social behavior60.
If an X-linked imprinted locus is responsible for social behavior differences this may
explain why males tend to be affected more often than females by pervasive
developmental disorders affecting social behavior, such as autism.
Researchers proposed that a maternal imprint on the X chromosome lowers the
threshold for phenotypic expression of the genes predisposing an individual to autism61.
Particularly, this explains the male vulnerability to autism. Looking at this proposal
another way, the imprint protects females from developing the disorder.
Another theory is the Baron-Cohen fetal testosterone exposure theory62. BaronCohen proposed that fetal exposure to high androgen levels is associated with increased
severity of some autistic traits, irrespective of sex chromosome constitution. He called
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this the “extreme male brain.” The male brain type is defined as one that is superior in
understanding physical objects over social common-sense; a female brain type is opposite
of this. Individuals are assumed to fall within a continuum in regard to male and female
brain types. Furthermore, an individual may be “cognitively balanced” where they show
equal male and female brain types. Baron-Cohen suggested that autistic individuals have
an extreme male brain type, regardless of sex. Depending on how extreme the male brain
type is, an individual would fall on a continuum ranging from a touch of autism to
classical autism. It remains controversial as to the neurobiological composition of a male
versus female brain.

3.2 Human Lymphoblast Studies
As described previously, oxidative stress has been implicated in the pathogenesis
of autism. My study indicates that TKTL1 overexpression increases oxidative stress,
providing a potential connection to autism. Consequently, I aimed to determine if there is
a higher level of TKTL1 expression in relation to autism.
Family studies were executed for comparison of TKTL1 expression levels in
autistic individuals versus their unaffected siblings. Human lymphoblastoid cell lines
were obtained from Rutgers University Cell and DNA Repository. The cell lines
belonged to individuals affected with autism or ASD (as diagnosed by the DSM-IV) and
their unaffected siblings.
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TKTL1 Expression Results
The lymphoblastoid cell lines of siblings from six pedigrees were brought up in
cell culture according to procedures provided by Rutgers University Cell and DNA
Repository (Protocol 8). Total RNA was extracted from the obtained lymphoblastoidal
cell pellets and was analyzed for TKTL1 expression by real-time RT-PCR (Protocol 9).
All real-time RT-PCR results are located in Supplemental Figures 2 through 8. The realtime RT-PCRs were repeated one or more times from the same total RNA.
The graphs in Figures 3.1 through 3.4 represent the autistic and unaffected males
from the pedigrees that contained both types of males. We were more interested in
comparing males to each other because of skewed X-inactivation patterns in female
lymphoblastoid cell lines. Female lymphoblastoid cell lines tend to be mostly XiX or
XXi, whereas male lymphoblastoid cell lines will always have an active maternal X
chromosome. Since TKTL1 is imprinted on the paternal X-chromosome, X-inactivation
patterns in the cultured female lymphoblasts may therefore skew the TKTL1 expression
results.
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Pedigree 72-0890

Relative Expression Ratio

Pedigree 72-0890
10
9
8
7
6
5
4
3
2
1
0

8.5005

2.0426

3.3630
2.9093

Male
03C23228

Autistic Male
03C23215

Autistic Male
03C23216

Male
03C23218

Figure 3.1 Real-time RT-PCR results for TKTL1 expression in autistic and unaffected
males for pedigree 72-0890. Error bars indicate a 95% confidence interval.

Pedigree 72-0890 displayed autistic male 03C23215 as having the highest TKTL1
expression level. Following, autistic male 03C23216 and unaffected male 03C23218 had
similar expression levels to each other. Unaffected male 03C23228 displayed the lowest
TKTL1 expression; however the 95% confidence interval was very large.

35

Pedigree 74-0264

Relative Expression Ratio

Pedigree 74-0264
18
16
14
12
10
8
6
4
2
0

12.9804

3.1748
1.3449
Male
03C16522

Autistic Male
03C16523

Male
03C16525

Figure 3.2 Real-time RT-PCR results for TKTL1 expression in autistic and unaffected
males for pedigree 74-0264. Error bars indicate a 95% confidence interval.

Unaffected male 03C16525 displayed the highest TKTL1 expression level in
pedigree 74-0264. The other unaffected male, 03C16522, had the lowest expression,
while autistic male 03C16523 displayed an expression level in between the unaffected
males, though closer to 03C16522.
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Pedigree 61-3511

Pedigree 61-3511
Relative Expression Ratio

6
3.8089

5
4
3

1.8669

1.8916

1.8972

2
1
0
Male
01C06843

Male
01C06848

Autistic Male
01C06844

Autistic Male
01C06845

Figure 3.3 Real-time RT-PCR results for TKTL1 expression in autistic and unaffected
males for pedigree 61-3511. Error bars indicate a 95% confidence interval.

An autistic male (01C06845) again displayed the highest expression of TKTL1 in
pedigree 63-3511. The other autistic male (01C06844) and the unaffected males
(01C06843 and 01C06845) had expression levels similar to each other but lower than
autistic male 01C06848.
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Pedigree 63-156

Pedigree 63-156
Relative Expression Ratio
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2.1033

2.5

1.6874

2.0
1.5
1.0
0.5
0.0
Male
01C07337

Autistic Male
01C07335

Figure 3.4 Real-time RT-PCR results for TKTL1 expression in autistic and unaffected
males for pedigree 63-156. Error bars indicate a 95% confidence interval.

Finally, pedigree 63-156 contained one unaffected male and one autistic male.
They appear to similarly express TKTL1; however there may be a chance that male
01C07337 expresses TKTL1 at a higher level than autistic male 01C07335. The large
error bars make this relationship difficult to determine.
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TKTL1 Expression Analysis
It appears that autistic males may have approximately equal or higher TKTL1
expression than unaffected male siblings, with one exception. Autistic male 03C16523 in
pedigree 74-0264 had lower expression than one of his unaffected brothers (03C16523).
The results for the males analyzed in the above four pedigrees were analyzed
together and combined into autistic and control (unaffected) groups. Figure 3.5 displays
the individuals’ TKTL1 expression levels along with their averaged expression. The two
groups appear to have similar TKTL1 expression according to this analysis, with a fairly
similar distribution of individual expression. A one-tailed T-test determined that there
was no significant difference of TKTL1 expression between autistic and unaffected
groups (P = 0.41417).

Figure 3.5 TKTL1 expression in autistic and control (unaffected) males from pedigrees
72-0890, 74-0264, 61-3511 and 63-156. Diamonds indicate individual expression levels
for each male. Error bars indicate standard error.
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An analysis of variance (ANOVA) was performed by Dr. Nathaniel Jue to further
analyze the data. The results of the ANOVA are provided in Tables 3.1 and 3.2. The test
indicates that there is no significant difference of TKTL1 expression between autistic and
unaffected individuals. Additionally, both autism (fixed factor) and family (random
factor) have no significant effect on TKTL1 expression.

Source DF Sum of Squares Mean Square F Ratio
Model
4
16.888646
4.22216
0.7623
Error
8
44.309982
5.53875 Prob > F
C. Total 12
77.814871
0.5782
Table 3.1 Analysis of Variance.

Source
Nparm DF DFDen Sum of Squares F Ratio Prob > F
Autistic
1
1
8
0.20472 0.0368
0.8526
FamilyID & Random
4
3
8
16.545622 0.9957
0.4428
Table 3.2 Effects Tests.

Discussion
The information in Figure 3.5 and Tables 3.1 and 3.2 suggests that TKTL1
expression differences do not exist between autistic and unaffected individuals. However,
it must be taken into account that the sample size is relatively small. In total, thirteen
males from four families were included in the above figure, which may not be
representative of the larger population. The potential differences in TKTL1 expression
that are implicated in Figures 3.1 through 3.4 may also be misleading because of two
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problems: real-time RT-PCR Ct values varied within triplicates for an individual and
relative expression ratios varied for an individual between trials.
Observation of the Ct values for both GAPDH and TKTL1 revealed variation
within the triplicates for a single individual. Variation could be attributed to poor primer
design or old primers that degraded. Originally, polyA selected mRNA had been used for
real-time RT-PCR, along with a different TKTL1 primer set. TKTL1 was difficult to
amplify with these primers and produced poor melt curves. I discovered that the forward
primer of that set had been designed to pick up a wild type SNP in the 5’ UTR of TKTL1.
With this knowledge, I decided that this was an unacceptable primer set to use and
instead made a primer set spanning exons 4 and 5 of the gene. The new primer set
amplified TKTL1 well from total RNA and the polyA mRNA selection was abandoned.
For a period of time the Ct values had little variation within the triplicates, however
within two months the Ct values started to vary. Since the GAPDH Ct values had not
previously varied, I ordered the same primers again. Even with fresh primers the Ct
values continued to vary within triplicates. Re-ordering the same GAPDH primers
demonstrated that the variation was probably not due to degraded primers seeing as the
issue persisted. It is also interesting to note that both sets of primers had previously
amplified the genes well and consistently.
The variation of Ct values within the triplicates for a single individual and the
occurrence of this happening for both primer sets caused two problems with the real-time
RT-PCR results. First, many error bars on the graphs are very large, meaning that the
95% confidence intervals are very large. Repeating the real-time RT-PCRs did not fix
this, however repetition caused the second problem to become apparent. Between trials
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the relative expression of TKTL1 among individuals changed even though the same RNA
was used. For example, in pedigree 61-3511 on 3/30/11 autistic male 01C06844
displayed higher TKTL1 expression than male 01C06848; however that relationship
switched on 3/31/11 (Supplemental Figure 2.6). For this reason I took into account the
data from all repetitions of pedigrees 61-3511 and 63-156 for the above analysis of
unaffected males versus autistic males, however in actuality the relationships may be
different. The data from only one trial each of pedigrees 72-0890 and 74-0264 was used
for the above analysis because even larger error bars would have been introduced if more
data was included. Again, the relationship between individuals may not be accurately
represented.
While GAPDH has been used as a reference gene in many publications, 18S
rRNA is less variable in expression level than GAPDH and therefore may be a better
candidate for a reference gene. GAPDH mRNA levels are not constant63 and expression
level variability was found in Epstein-Barr virus-transformed lymphoblastoid cell lines64.
Another possibility is that both primer sets were poorly designed and for an unknown
reason were able to consistently amplify for some triplicates in earlier real-time RTPCRs. Primer instability and degradation are also concerns. Fresh primer dilutions were
made for each real-time RT-PCR, introducing freeze-thaw effects. Masters mixes were
used whenever possible to prevent sample-to-sample and well-to-well variability;
however automation of the sample preparation would reduce inconsistencies. It is also
possible that the RNA degraded over time, possibly due to freeze-thawing the RNA on
multiple occasions, or possible nuclease contamination. Variability could also be caused
by lot-to-lot inconsistencies of reverse transcriptase and SYBR® Green65.
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An alternative explanation exists for the varied TKTL1 expression between
autistic and unaffected males between pedigrees. The variation could be due to an
interaction between autism and family. TKTL1 may be contributing to autism only in
some families while in others it has little or no effect. The intersecting lines in the graph
in Figure 3.6 demonstrate a potential interaction between autism and family. However,
the interaction between a fixed and random variable cannot be tested for given the
experimental design and statistical approach implemented in this study.

Mean TKTL1 Expression

Figure 3.6 Graph depicting the autistic and control mean relative TKTL1 expression ratio
in each family. FamilyIDs: 1 = 74-0264, 2 = 61-3511, 3 = 63-156, 4 = 72-0890.
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Chapter 4: Synopsis
Oxidative stress has been implicated in the pathogenesis of autism. The pentose
phosphate pathway is responsible for combating oxidative stress by reducing glutathione,
which subsequently reduces free radicals. Previous studies have shown a decreased
GSH/GSSG ratio and an increased free radical generation in lymphoblastoid cells of
autistic and unaffected individuals45. Additionally, the amount of reduced glutathione in
the cell is decreased when transaldolase is overexpressed42. Combined, there is reason to
believe that TKTL1 overexpression causes a decreased ability of the cell to reduce
glutathione.
Overexpression of TKTL1in this study significantly decreased the GSH/GSSG
ratio in the cell, indicating a heightened state of oxidative stress. It was thought that the
NADPH/NADP+ ratio would decrease as well, however inconclusive results were
obtained and further testing is required. G6pdx expression, however, did decrease upon
TKTL1 overexpression. The decrease of both the GSH/GSSG ratio and G6pdx expression
lead me to hypothesize that the NADPH/NADP+ ratio actually decreases as well.
Skuse et al. suggested that an X-linked imprinted gene is involved in autism60,
leading us to analyze autistic and unaffected individuals for TKTL1 expression
differences. It was thought that TKTL1 expression may be higher in autistic individuals
because of its apparent effect on oxidative stress; however no conclusive deduction could
be made about TKTL1 expression differences between individuals.
Potential autism susceptibility genes have been analyzed directly in brain tissue
using real-time RT-PCR66. Since the brain is highly susceptible to the effects of oxidative
stress, analysis of TKTL1 expression in brain tissue would prove highly informative.
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Chapter 5: Methods

Protocol 1: TKTL1 Expression Construct Formation
The full-length human TKTL1 CDS (Open Biosystems clone #4825931) was
inserted into a pCAGGS vector (Supplemental Figure 1), which contains a chicken βactin promoter. Both were digested with EcoRI and then ligated together with T4 DNA
ligase as per standard methods. Successful construct formation was determined by
BamHI digest and DNA sequencing. The hTktl1 primers used for sequencing can be
found in Supplemental Table 1.

Protocol 2: Expression of TKTL1
The TKTL1 expression construct (hTktl1-pCAGGS) was co-transfected with
GFP-pCAGGS into HT-22 cells, a mouse hippocampal cell line. T75 flasks were seeded
with 1x106 cells in 10mL of media (DMEM, 10% FBS, 1% L-glutamine, 1%
penicillin/streptomycin) and incubated overnight at 37˚C, 5% CO2. A transfection mix
was then prepared with 750µl DMEM, 3µl LipofectamineTM PLUSTM Reagent, 1µg GFPpCAGGS and 1µg control (empty pCAGGS vector) or hTktl1-pCAGGS. This was
incubated at room temperature for 5 minutes, then 9µl of LipofectamineTM LTX was
added and this was incubated at room temperature for 30 minutes. The transfection mix
was added to the T75 flasks along with 3mL of media (DMEM, 10% FBS, 1% Lglutamine) and incubated for 5 hours at 37˚C, 5% CO2. The media was then changed to
the antibiotic-containing media above. The cells were incubated for 3 days, with a media
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change on day 2. On day 3 the cells were imaged and harvested. The cells were harvested
in ice cold 1x PBS using a rubber policeman. Cell pellets were stored at -80˚C.

Protocol 3: Western Blot
Western blot was performed using cell pellets and established protocols. The
primary antibody was a monoclonal mouse anti-human TKTL1 antibody (Abcam®). The
secondary antibody was stabilized Peroxidase Conjugated Goat anti-Mouse (H + L)
(Thermo Scientific). After blotting, proteins were detected using Western Lightning®
Plus-ECL (PerkinElmer).

Protocol 4: Total RNA Extraction
Total RNA was extracted from cell pellets using the RNeasy Mini Kit (QIAGEN)
as per manufacturer’s instructions. The RNA was subsequently DNased using TURBO
DNA-free™ (Ambion®).

Protocol 5: Real-Time RT-PCR
cDNA synthesis was performed with 1µg of RNA using a qScript cDNA
Synthesis kit (Quanta BioSciences, Inc.™) as per manufacturer’s protocol. Real-time RTPCR was performed using PerfeCTa® SYBR® Green FastMix® for iQ (Quanta
BioSciences, Inc.™) and primers “AF TKTL1 F1” and “AF TKTL1 R1” for
TKTL1/Tktl1, “G6pd F” and “G6pd R” for G6pdx, and “MF3” and “MR3” for mouse βactin (Supplemental Table 1). The cycling conditions were as follows: 95˚C for 3 min, 40
cycles of 95˚C for 10 secs and 63.5˚C (for TKTL1/Tktl1) or 63˚C (for G6pdx) for 30 secs,
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95˚C for 1 min, 55˚C for 1 min, 80 cycles of 55˚C for 10 secs + 0.5˚C/cycle.
Mathematical analysis of real-time RT-PCR data was carried out as described by
normalizing and comparing Ct values of the genes of interest to -actin67.

Protocol 6: Glutathione Assay
Cell pellets were homogenized in the appropriate buffer and then deproteinated
using metaphosphoric acid (Sigma-Aldrich®). Deproteinated samples were assayed with
the Glutathione Assay Kit (Cayman Chemical). As per manufacturer’s instructions, total
GSH was detected via a colorimetric reaction with DTNB. GSSG was detected by
addition of 2-vinylpyridine (Sigma-Aldrich®) prior to assaying. A 96-well plate reader
was used to measure the absorbance at 405nm at 5 minute intervals over a period of 30
minutes. The 25 minute read was used for the end-point analysis. End point analysis:
[(sample absorbance – standard y-intercept) / (standard slope)] * 2. All values were
determined per manufacturer’s protocol.

Protocol 7: NADP+/NADPH Assay
Cell pellets were homogenized in provided buffers from the EnzyChrom™
NADP+/NADPH Assay Kit (BioAssay Systems). As per manufacturer’s protocol,
NADP+ and NADPH were measured via a colorimetric reaction based on the ability of
NADPH to reduce tetrazolium dye (MTT). A 96-well plate reader was used to measure
the absorbance at 565nm at time “zero” and after a thirty minute incubation at room
temperature. OD0 was subtracted from OD30 and the ∆OD was used to calculate the
NADP+ and NADPH concentrations using the standard curve.
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Protocol 8: Human Lymphoblastoid Cell Culture
Human lymphoblastoid cell lines were received from Rutgers University Cell and
DNA Repository at Rutgers, The State University of New Jersey, per NIMH permission.
The cell lines consisted of lymphoblasts from individuals affected with autism or ASD
(as diagnosed by the DSM-IV) and unaffected siblings. The cell lines were received as
1mL aliquots cryopreserved in 45% RPMI-1640, 50% FBS and 5% DMSO.
10mL of fresh media (88% RPMI-1640, 10% FBS, 1% penicillin/streptomycin
and 1% nonessential amino acids) was added to T-75 flasks. The cell lines were thawed
at 37˚C and pipetted into one flask each. 10mL of media was added to each flask 24
hours later. Fresh media was added as needed to maintain a cell density between 200,000
cells/mL and 500,000 cells/mL. Cells were collected as necessary.
When collected, the cell lines were either frozen down or stored as pellets. In both
cases, the cell suspension was centrifuged at 1,000 x g for 5 minutes at 4˚C and then the
media was removed. To freeze down, the cells were resuspended in freezing media (90%
media from above and 10% DMSO) and 1mL aliquots were stored in cryotubes in liquid
nitrogen. The cell pellets were stored at -80˚C.

Protocol 9: Human Lymphoblastoid Real-Time RT-PCR
Total RNA was extracted from the human lymphoblastoid cell pellets using
TRIzol®. Subsequently cDNA was prepared as per manufacturer’s protocol (qScript™
cDNA Synthesis kit, Quanta BioSciences, Inc.™). Real-time PCR was performed using
PerfeCTa ® SYBR® Green FastMix® for iQ (Quanta BioSciences, Inc.™) as per usual
methods using the primers “AF hTktl1 F14” and “AF hTktl1 R14” for TKTL1 and
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“hGAPDH F” and “hGAPDH R” for GAPDH (Supplemental Table 1). The cycling
conditions were as follows: 95˚C for 3 min, 40 cycles of 95˚C for 10 secs and 63˚C for 30
secs, 95˚C for 1 min, 55˚C for 1 min, 80 cycles of 55˚C for 10 secs + 0.5˚C/cycle.
Mathematical analysis of the data was carried out as described by normalizing the Ct
values of TKTL1 to GAPDH and comparing the relative expression ratios67.
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Figure 1 pCAGGS vector map. Commercially available expression vector used for
TKTL1 transfection into HT-22 cells. The TKTL1 CDS was inserted at the EcoRI sites.
Image provided by the LoTurco laboratory.
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Pedigree 72-0890

Pedigree 72-0890 (4/15/11)
Relative Expression Ratio
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03C23223
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Autistic
Male
03C23215
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03C23216

Male
03C23218

Pedigree 72-0890 (4/19/11)
Relative Expression Ratio
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60
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40
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30
20
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11.3639

9.8306
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Male
03C23216

Male
03C23218

1.1537

0
Female
03C23212

Autistic
Female
03C23223

Male
03C23228

Autistic
Male
03C23215

Figure 2 Two separate real-time RT-PCR trials of pedigree 72-0890. Error bars indicate
a 95% confidence interval.
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Pedigree 72-1650

Relative Expression Ratio
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Autistic
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Relative Expression Ratio

Pedigree 72-1650 (3/30/11)
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60

45.7287

50
40
23.4964
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20

15.6621

10

5.1338
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Autistic
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06C53576

Autistic
Male
06C53572

0
Female
06C53575

Autistic
Male
06C53577

Female
06C53582

Autistic
Female
06C53583

Figure 3 Two separate real-time RT-PCR trials for pedigree 72-1650. Error bars indicate
a 95% confidence interval.
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Pedigree 74-0264

Relative Expression Ratio

Pedigree 74-0264 (4/1/11)
100
90
80
70
60
50
40
30
20
10
0

77.1315

2.9518
Female
03C15169

Autistic Male
03C15168

7.9887

Autistic Female
03C15167

Figure 4 Real-time RT-PCR results for one trial of half of pedigree 74-0264. These
individuals are cousins with the other half of this pedigree (shown below). Error bars
indicate a 95% confidence interval.
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Pedigree 74-0264 (3/27/11)
Relative Expression Ratio
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0
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Pedigree 74-0264 (3/28/11)
Relative Expression Ratio
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60
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20
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0
Male
03C16522

Female
03C16526

Autistic Male
03C16523

Male
03C16525

Figure 5 Real-time RT-PCR results for two separate trials of half of pedigree 74-0264.
These individuals are cousins with the other half of this pedigree (shown above). Error
bars indicate a 95% confidence interval.
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Pedigree 63-302

Pedigree 63-302 (3/31/11)
Relative Expression Ratio

2.5
1.8118

2.0
1.5

1.2388

1.0
0.5

NA

NA

0.0
Autistic Male
01C05904

Autistic Female
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Autistic Female
01C05902

Autistic Male
01C05905

Pedigree 63-302 (4/1/11)
Relative Expression Ratio

2.5
1.6908

2.0
1.5

1.0965

1.0
0.5

NA

NA

Autistic Female
01C05902

Autistic Male
01C05905

0.0
Autistic Male
01C05904

Autistic Female
01C05903

Figure 6 Real-time RT-PCR results for two separate trials of pedigree 63-302. Data was
not available for Autistic Female 01C05902 and Autistic Male 01C05905. Error bars
indicate a 95% confidence interval.
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Pedigree 61-3511

Relative Expression Ratio

Pedigree 61-3511 (3/30/11)
3.5
2.5100

3.0
2.5
2.0
1.5

1.5860
1.0421

1.2503

1.0664

1.0
0.5
0.0
Male
01C06843

Male
01C06848

Autistic Male
01C06844

Female
01C06842

Autistic Male
01C06845

Relative Expression Ratio

Pedigree 61-3511 (3/31/11)
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Relative Expression Ratio

Pedigree 61-3511 (4/8/11)
20
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15
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7.2235
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5

1.9568

0
Male
01C06843

Male
01C06848

Autistic Male
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Female
01C06842

Autistic Male
01C06845

Figure 7 Real-time RT-PCR results for three separate trials of pedigree 61-3511. Error
bars indicate a 95% confidence interval.
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Pedigree 63-156

Relative Expression Ratio

Pedigree 63-156 (4/1/11)
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Pedigree 63-156 (4/20/11)
Relative Expression Ratio
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20
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Autistic Male
01C07335

1.1303

0
Male
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Female
01C07336

Autistic
Female
01C07333

Figure 8 Real-time RT-PCR results for two separate trials of pedigree 63-156. Data was
not available for Female 01C07334 on 4/1/11. Error bars indicate a 95% confidence
interval.
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Primer Name

Sequence (5'→ 3')

Gene

M13 F
M13 R
AF pCAGGS F4
hTktl1 F7 (Operon)
hTktl1 F7 (Invitrogen)
hTktl1 F11
hTktl1 R3
hTktl1 R5
hTktl1 R10
hTktl1 R13
hTktl1 R15
hTktl1 R16
Actb MF3
Actb MR3
AF TKTL1 F1
AF TKTL1 R1
G6pd F
G6pd R
hGAPDH F
hGAPDH R
AF hTktl1 F14
AF hTktl1 R14

CAGGAAACAGCTATGAC
GTAAAACGACGGCCAG
TTCAGACTCCAAAGGGGTTG
ATGCCGAGAGAAAGAGCAGA
GCATATGCAAGTACCGCTCT
GAGGCGAGGGCTGAGTTC
AAACATAAACACAGGGTAAAGAGGC
TTCTGAGGACTCGCCATCACTC
TTCAATCCACATTTTCTTTACTCATG
GGCATCTGCTCTTTCTCTCG
AATTCCTCGGACTTCCCACT
CGGATTCTCTGGATCTGACTG
ACACCCGCCACCAGTTCG
CGATGGAGGGGAATACAGCC
ATGTGGCAACAGGATGGC
TGGTCTGTATCTGGCTCTCAATTAA
AGCCTCCTATAAGCACCTCAACAGCC
TCCACGATGATGCGGTTCCAGC
AACTTTGGTATCGTGGAAGG
ACACGTTGGCAGTGGGGACA
TCTGTCTGGGAGGCAATGGCC
TCCCGGCCGTCCACCACATAA

Vector
Vector
pCAGGS Vector
TKTL1
TKTL1
TKTL1
TKTL1
TKTL1
TKTL1
TKTL1
TKTL1
TKTL1
β-Actin
β-Actin
TKTL1/Tktl1
TKTL1/Tktl1
G6pdx
G6pdx
GAPDH
GAPDH
TKTL1
TKTL1

Table 1 Name, sequence and gene for the primers used throughout the thesis.
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Trial # Control/Sample Average GSH/GSSG Standard Deviation
Control
NA
NA
1
Sample
NA
NA
Control
NA
NA
2
Sample
NA
NA
Control
7.32768
0.42949
3
Sample
2.82402
0.15848
Control
NA
NA
4
Sample
NA
NA
Control
NA
NA
5
Sample
NA
NA
Control
8.95068
1.23647
6
Sample
1.34007
0.12721
Control
1.23923
0.12119
7
Sample
1.27867
0.21110
Control
9.14736
0.25454
8
Sample
6.02062
0.21985
Control
3.49679
0.09919
9
Sample
3.36254
0.11754
Table 2 Glutathione assay results. “NA” (Not Applicable) in the GSH/GSSG column
means that the ratio could not be determined because the GSSG concentration was
negative.

Trial # Control/Sample Average NADPH/NADP+ Standard Deviation
Control
0.67111
0.25864
1
Sample
0.90285
0.04089
Control
1.03492
0.19806
2
Sample
0.51953
0.06389
Control
5.37500
NA
3
Sample
0.79070
NA
Control
0.62909
0.02542
4
Sample
0.46992
0.02570
Control
0.23906
0.02241
5
Sample
0.30233
NA
Table 3 NADP+/NADPH assay results. “NA” indicates that the standard deviation could
not be calculated because only one sample in the triplicate provided usable data.
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